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Mesenchymal stem cells (MSCs), represent an attractive tool for the establishment of a successful stem-cell-based therapy of liver
diseases.AnumberofdiﬀerentmechanismscontributetothetherapeuticeﬀectsexertedbyMSCs,sincethesecellscandiﬀerentiate
intofunctionalhepaticcellsandcanalsoproduceaseriesofgrowthfactorsandcytokinesabletosuppressinﬂammatoryresponses,
reduce hepatocyte apoptosis, regress liver ﬁbrosis, and enhance hepatocyte functionality. To date, the infusion of MSCs or MSC-
conditioned medium has shown encouraging results in the treatment of fulminant hepatic failure and in end-stage liver disease in
experimental settings. However, some issues under debate hamper the use of MSCs in clinical trials. This paper summarizes the
biologicalrelevanceofMSCsandthepotentialbeneﬁtsandrisksthatcanresultfromtranslatingtheMSCresearchtothetreatment
of liver diseases.
1.Introduction
The liver has a remarkable regenerative capacity in response
to acute injury. Mature hepatocytes can reenter the cell
cycle and undergo several cell divisions to restore the
hepatic mass. However, following chronic liver damage, the
regenerative ability of hepatocytes is lost. In such conditions,
the liver is unable to maintain its functional mass; this is
clinically mirrored by the so-called “liver failure.” Currently,
orthotopic liver transplantation (OLT) represents the most
suitable therapeutic option for patients with advanced liver
diseases and hepatic failure. Nevertheless, only a minority of
candidates undergo OLT, given the organ shortage. Hence,
alternative strategies for the treatment of decompensated
liver diseases are needed to be developed [1].
Cell-based therapy has been proposed as a potential
alternative to OLT. Indeed, it has been known for more
than 30 years that hepatocytes isolated from a donor liver
and infused intraportally in animal models of liver damage
can be engrafted into the recipient hepatic parenchyma and
express metabolic activity. These results have encouraged
clinical trials using hepatocytes transplantation to treat a
variety of liver diseases [2]. The best outcome of allogeneic
hepatocytes transplantation was reported for the treatment
of acute liver failure, in which hepatocytes infusion provides
the rapid metabolism of liver toxins and the stabilization
of hemodynamic parameters. However, transplantation of
livercellsprovidesseriouspracticalproblems:donorscarcity,
risk of rejection, low hepatocyte viability (only 30% of
hepatocytes survive transplantation) and inability maintain
and amplify cell cultures [3, 4].
Given this background, a growing enthusiasm has
greeted the development of stem-cell-based therapies for
liver diseases. In particular, transplantation of hematopoietic
bone marrow (BM) stem cells and mesenchymal stem cells
(MSCs)has been extensively investigated aspotential sources
for liver regeneration.
In 1999, Petersen et al. ﬁrst showed that liver stem cells
might be derived from BM, in a rat model of liver injury [5],
and it was suggested that BM could contribute to the mature2 Journal of Biomedicine and Biotechnology
hepatocyte population. Subsequent studies have shown that
BM-derived hepatocytes might arise from cell fusion and
not only by direct diﬀerentiation [6] and that BM cells give
a limited contribution to the hepatocyte population, under
physiological conditions or in response to mild injury [7].
MSCs represent another promising candidate for liver
stem cell therapy. Several studies have demonstrated that
MSCs can diﬀerentiate in vitro along the hepatogenic lineage
[8,9].Todate,studiesonanimalmodelsreportedthebeneﬁ-
cial eﬀect of MSCs in promoting hepatic tissue regeneration.
Kuo et al. have shown that both MSC-derived hepatocytes
andMSCs,transplantedbyeitherintrasplenicorintravenous
route, can be engrafted into the recipient liver and diﬀerenti-
ate into functional hepatocytes. Intravenous transplantation
was more eﬀective in rescuing liver failure than intrasplenic
transplantation. Moreover, MSCs were more resistant to
reactive oxygen species in vitro, reduced oxidative stress in
recipient mice, and accelerated repopulation of hepatocytes
after liver damage, suggesting a possible role for paracrine
eﬀects [10]. These results have been conﬁrmed also by Banas
et al., who evaluated the therapeutic potential of MSCs
for the treatment of liver failure and postulated that the
beneﬁcial eﬀects of human MSC transplantation were due at
least in part to the cells’ ability to produce a large number
and volume of bioactive factors [11]. To date, only a few
clinical trials have been performed in patients with end-
stage liver disease caused by hepatitis B, hepatitis C, and
alcoholic ﬁbrosis. The results of these studies have shown
that MSC injection can be used for the treatment of end-
stageliverdiseases,withsatisfactorytolerabilityandclinically
relevant eﬀects [12]. Nonetheless, these studies have not
provided deﬁnitive evidence that MSCs have a capability
to diﬀerentiate into functional hepatocytes in vivo [13],
because the observed improvements could be attributed to
the secretion of soluble growth factors by MSCs, rather
than to their transdiﬀerentiation into hepatocytes [7]. MSC
cells have also emerged as promising candidate cells for
immunomodulation therapy, especially in the setting of liver
transplantation,giventheirabilitytointeractatvariouslevels
with the immune system [14, 15].
Overall, a number of diﬀerent mechanisms contribute
to the therapeutic eﬀects exerted by MSCs, which can
diﬀerentiate into functional hepatic cells and also produce
a series of growth factors and cytokines that can sup-
press inﬂammatory responses, reduce hepatocytes apoptosis,
regress liver ﬁbrosis, and enhance hepatocytes functionality
[16].
2.MSCProperties
MSCs were ﬁrst described by Friedenstein in the early 1990s,
as an adherent, ﬁbroblastoid cell population that showed
inherent osteogenic properties [17]. Numerous studies have
demonstrated that MSCs have a high degree of plasticity,
as they diﬀerentiate into cells of the mesenchymal lineage,
buttheycanalsotransdiﬀerentiateintoneurons,splenocytes,
and various epithelial cells, including lung, liver, intestine,
and kidney cells. BM was originally considered the reference
source for MSC isolation, although they have been isolated
from a multitude of adult tissues, including muscle, adipose
tissue, connective tissue, trabecular bone, synovial ﬂuid,
along with perinatal tissues, such as umbilical cord, amniotic
ﬂuid, and placenta [18]. In particular, adipose tissue (AT)
has several advantages compared to other adult tissues as
a source of MSCs. Indeed, AT is abundant and can be
easily removed by simple lipoaspirate. Moreover, adipose-
tissue-derived MSCs (AT-MSCs) can be maintained longer
in culture and possess a higher proliferation capacity than
BM-derived MSCs. Thus, AT may be an ideal source of large
numbers of autologous stem cells [19].
MSCs do not express the hematopoietic surface markers
CD34 and CD45, but stain positive for CD44, CD29, CD105,
CD73, and CD166 [20]. Moreover, MSCs express human
leukocyte antigen (HLA) class I, but not HLA class II, and
secrete several extracellular matrix (ECM) molecules, such
as collagen, ﬁbronectin, laminin, and proteoglycans. For
this reason it has been postulated that MSCs might play a
central role in ECM organization. We performed a high-
throughput molecular analysis of BM- and AT-MSCs. The
gene expression proﬁle analysis has revealed that they share
190coherentlymodulatedtranscripts,whichmightrepresent
the molecular “MSC stemness signature.” Among them, we
found several genes involved in basic biologic mechanisms,
such as embryogenesis, organogenesis, signal transduction,
cell adhesion, stress response, and transcription regulation.
In particular, a key role in determining the outcome of
MSC fate determination is played by KLF4, highlighting the
speciﬁc binding of KLF4 to regulatory sequences of genes
involved in adult stem cell maintenance [19].
BM-derivedMSCsareknowntonaturallysupporthema-
topoiesisbysecretinganumberoftrophicmolecules,includ-
ing soluble extracellular matrix glycoproteins, cytokines, and
growth factors [21, 22]. Recent studies have demonstrated
that MSCs can produce some antiapoptotic cytokines such
as stromal-cell-derived factor-1 and vascular endothelial
growthfactor,whicheﬃcientlyreducetheapoptosisofrecip-
ient cells via the stromal cell-derived factor-1/CX chemokine
receptor-4 axis. The antiapoptotic eﬀects of MSCs have been
observed in liver injury models [23–26]. Furthermore, MSCs
can secrete several cytokines such as hepatocyte growth
factor (HGF), epidermal growth factor, IL-6, and TNF-α;
in turn, these cytokines stimulate hepatocyte proliferation
and maintain hepatocyte function, as indicated by the high
levels of albumin and urea secretion granted upon MSC
transplantation [27]. Finally, MSCs can produce a series of
cytokines and signal molecules that can potentially suppress
inﬂammatory responses such as IL-1 receptor antagonists
and can upregulate anti-inﬂammatory cytokines such as IL-
10 [25].
3.MSC Plasticity
Given their wide diﬀerentiation potential and their self-
renewal capacity, MSCs have been considered a promising
candidate for cell-based therapy and tissue engineering.
Moreover, these cells have the ability to proliferate to an
extensive but ﬁnite degree, an important characteristic thatJournal of Biomedicine and Biotechnology 3
shouldreduceconcernsaboutpotentialtumorigenicityupon
in vivo transplantation.
The high degree of plasticity of MSCs has been widely
demonstrated during the last decade [28–31]. In particular,
in vitro models, using culture medium supplemented with a
cocktail of growth factors, were used to successfully induce
the transdiﬀerentiation of MSCs into hepatic cells with
functional properties, such as the production of albumin
and urea, along with glycogen storage [32]. Moreover, the in
vivo transdiﬀerentiation of MSCs into hepatic cells has been
described in rats [33], mice [34], and humans [35].
Seo et al. ﬁrst reported that human AT-MSCs injected
into SCID mice, following toxic liver damage, were able to
diﬀerentiate into hepatocyte-like cells [36]. Several reports
have conﬁrmed the possibility of generating hepatocyte-like
cells from AT-MSCs [37, 38]. In particular, in a xenogeneic
transplantation model of liver regeneration, the engraftment
of AT-MSCs prediﬀerentiated in vitro to hepatocyte-like cells
was signiﬁcantly more eﬃcient versus undiﬀerentiated AT-
MSCs, and AT-MSCs were better candidates than BM-MSCs
for cell therapies [39].
We conﬁrmed that AT-MSCs can transdiﬀerentiate in
vitro into hepatocyte-like cells, using a two-step protocol
with sequential addition of growth factors. Under this
regimen, spindle-shaped ﬁbroblastoid cells diﬀerentiated to
a layer of compact polygonal epithelial cells. These cells
acquired speciﬁc liver functions, as shown by their ability
to store glycogen and to express hepatic-associated genes
and proteins. Moreover, the comparative high-throughput
molecular analysis of AT-MSCs, before and after hepato-
genic conversion, allowed the identiﬁcation of a complex
interplay between cell receptors, signaling pathways, and
transcription factors, responsible for tissue cross-lineage
conversion through the mesenchymal-epithelial transition
(MET). Our study showed that the AT-MSC plasticity is
dependent on MET and suggested that subtle regulations
of the canonical pathways of BMP, WNT, and TGF-β may
be important to allow MSCs to transdiﬀerentiate into other
lineages [40].
The pivotal role that MET plays in determining AT-
MSCs transdiﬀerentiation in hepatocytes was also conﬁrmed
in an interesting article by Yamamoto and colleagues [41].
The authors compared the transcriptomes of three cell
populations, undiﬀerentiated AT-MSCs, AT-MSC-derived
hepatocytes (AT-MSC-Hepa) and human primary hepato-
cytes, and human liver tissue, using microarray analysis.
The results indicated that AT-MSC-Hepa and hepatocytes
displayed a similar gene expression proﬁle, while undif-
ferentiated AT-MSCs showed a diﬀerent pattern. The list
of genes upregulated in AT-MSC-Hepa, liver cells, and
tissue comprised, in particular, genes encoding hepatocyte-
speciﬁc metabolic enzymes and markers [41]. Interestingly,
the microarray data indicated the downregulation of two
regulators of the epithelial-mesenchymal transition (EMT),
Twist and Snail, along with the upregulation of epithelial
markers, such as E-cadherin and a-catenin, in AT-MSC-
Hepa. In contrast, the expression of mesenchymal markers,
such as N-cadherin and vimentin, was downregulated. These
ﬁndings support the notion that MET is activated during the
hepatic diﬀerentiation of AT-MSCs, representing a pivotal
step for stem cell transdiﬀerentiation [41].
4.MSCs andImmune System
MSCsexpressfewHLAclassIandnoHLAclassIImolecules,
allowing them to evade allogeneic immune response. This
is the so-called “immunoprivilege,” an interesting feature
in MSC biology, which makes these cells extremely suitable
for both autologous and allogeneic transplantation [42].
Moreover, several studies have established that MSCs exert
a generally suppressive eﬀect on a wide variety of cells
belonging to both adaptive and innate immunity, including
T and B lymphocytes and natural killer cells (NKs). This
immunomodulatory eﬀect provides a rational basis for the
application of MSCs in the treatment of immune-mediated
diseases, such as graft-versus-host disease (GVHD). To date,
the mechanisms underlying this immunoregulation remain
unclear: some investigators suggested a cell-to-cell contact-
mediated suppression, while others hypothesized a soluble-
factor-mediated mechanism [43].
MSCs can suppress the activity of CD8+ cytotoxic T
lymphocytes both directly by inhibiting their proliferation
following antigen stimulation and indirectly by increasing
the relative proportion of CD4+ T helper-2 (TH2) lym-
phocytes and CD4+ regulatory T lymphocytes [44]. Since
B-lymphocyte activation is largely T cell dependent, the
inﬂuence of MSCs on T lymphocytes may also indirectly
s u p p r e s sB - c e l lf u n c t i o n s[ 45]. Additionally, MSCs exert a
direct inﬂuence on B-lymphocytes via cell-cell contact and
through secretion of paracrine molecules [46].
MSCs exert signiﬁcant eﬀects on the innate immune
system cells, including monocytes, dendritic cells (DCs),
macrophages, NKs, and neutrophils. The mechanisms by
which MSCs exert their inhibitory eﬀect on DC maturation
is still poorly deﬁned. Spaggiari et al. have shown in vitro
that MSCs inhibit the early stages of the progression from
monocytes to immature DCs, induced by interleukin-4 (IL-
4) and granulocyte-macrophage colony-stimulating factor
(GM-CSF). The authors have shown that diﬀerent soluble
factors mediate the inhibitory eﬀect exerted by MSCs, and
they provided a convincing evidence of the pivotal role
of prostaglandin E2 (PGE2) [47]. MSCs have a profound
inhibitory eﬀect on NK function, suppressing the IL-2-
induced cell proliferation, their cytolytic activity, and the
production of cytokines. MSCs can inhibit NK-cell function
via the production of soluble factors, including indoleamine
2,3-dioxygenase (IDO) and PGE2 [48]. Lastly, an in vitro
study demonstrated that MSCs inhibit apoptosis, expression
of adhesion molecules, and migration capability of neu-
trophils.Theseresultsareconsistentwiththehypothesisthat,
withintheBMniche,MSCsprotectneutrophilsofthestorage
pool from apoptosis, preserving their eﬀector functions.
Moreover, MSCs reduce intensity of the respiratory burst
preventing the excessive or inappropriate activation of the
oxidative metabolism. This may be a critical mechanism
through which MSCs can limit the severity of tissue damage
following ischemic and ischemia/reperfusion (I/R) injury
[49].4 Journal of Biomedicine and Biotechnology
5. Therapeutic Implicationsof MSC-Based
Treatments of LiverDiseases
ThetherapeuticpotentialitiesofMSCsarealsobasedontheir
inherent ability to home in sites of inﬂammation following
tissue injury when injected intravenously. This involves their
capability of migrating across endothelial cell layers and
being attracted to and retained in the ischemic tissue but
not in the remote or intact tissue. Although the mechanisms
driving this property are not fully understood, it is likely
that injured tissues express speciﬁc receptors or ligands that
facilitate traﬃcking, adhesion, and inﬁltration of MSCs to
the damaged site, similarly to leukocytes [50, 51]. It is well
known that chemokines are released after tissue damage
and that migratory direction follows the chemokine density
gradient. In this regard, it has been recently demonstrated
that MSCs express chemokine receptors and ligands that
are involved in leukocyte migration during inﬂammation,
including the stromal-derived factor-1 (SDF-1) chemokine
receptor(chemokine(C-X-Cmotif)receptor4,CXCR4)that
stimulates the recruitment of progenitor cells to the site of
tissue injury [52–55]. MSCs also express several adhesion
molecules that respond to SDF-1, as well as chemokines,
such as CX3CL1, CXCL16, CCL3, CCL19, and CCL21
[56–58]. Hence, the increase of inﬂammatory chemokine
concentration at the site of inﬂammation is a key mediator
of MSC traﬃcking to the site of injury [52]. In addition,
many integrins, selectins, and chemokine receptors involved
in the tethering, rolling, adhesion, and transmigration of
leukocytes have also been reported to be expressed on MSCs.
In particular, E- and P-selectin, CD44, and VCAM-1, which
function in leukocyte adhesion, have been shown to be
functionally important in the adhesion of MSCs to the
endothelium [59–61].
The therapeutic role of MSCs has been investigated us-
ing either autologous or allogeneic transplantation of cells,
which were previously expanded in culture and then intro-
duced intravenously or directly into the tissue of interest. To
date, infusion of MSCs has shown encouraging results in the
treatment of several immune- and inﬂammatory-mediated
conditions including GVHD, diabetes, and ulcerative colitis
and in the protection of solid organ grafts from rejection
[62]. Recent experimental studies have shown the successful
application of MSC transplantation in the treatment of
fulminant hepatic failure (FHF), end-stage liver disease
(ESLD), and inherited metabolic disorders (IMDs). These
studies have shown that MSC transplantation can partially
restore the liver function, ameliorate the symptoms, and
enhance the survival rates [8, 62].
Diﬀerent studies have shown that administration of
MSC-conditioned medium (MSC-CM), or MSC-derived
molecules, might function as alternative or adjuvant tool
versus MSC direct transplantation alone, for the treatment
of FHF [43, 62]. Indeed, Parekkadan et al. showed that
the administration of MSC-derived molecules, either by a
b o l u so fM S C - C Mo rb ye x t r a c o r p o r e a ls u p p o r tu s i n ga
bioreactor, signiﬁcantly improved short-term survival in a
D-galactosamine-induced rat model of FHF [62]. In another
study, van Poll et al. conﬁrmed the eﬀectiveness of MSC-CM
in a rat model of FHF. These authors demonstrated that
systemic infusion of MSC-CM provides signiﬁcant survival
beneﬁt and prevents the release of liver injury biomark-
ers [62]. Furthermore, MSC-CM therapy had profound
inhibitory eﬀects on hepatocellular death, resulting in a
90% reduction of hepatocyte apoptosis, and enhanced the
liver regeneration programs, incrementing the number of
proliferating hepatocytes. Taken together, these data support
the theory that MSC-CM induces an integrated beneﬁcial
response to liver damage [62]. Compared to MSC-CM,
transplanted MSCs have the capability to home in the site
of injury and ensure continued delivery of trophic signal
molecules. However, long-term engraftment rates are low,
and invasive methods for the local delivery of MSCs are
necessary [11, 63].
A study by Kanazawa and colleagues showed an inter-
esting application for MSCs in the treatment of the hepatic
I/R injury that occurs after liver transplantation [64]. These
authors reported that transplanted BM-MSCs were able to
amelioratehepaticI/Rinjuryandimproveliverregeneration,
in a rat model of Hepatectomy plus I/R; the cellular
treatment constrained the increase of serum transaminase
levels, the most sensitive marker for hepatic I/R injury
evaluation. In addition, a signiﬁcantly lower percentage of
apoptotic hepatocytes were observed in the MSCs group
compared with the controls. These ﬁndings suggested that
MSCs might have the potential to protect the liver against
I/Rinjury-inducedhepatocyteapoptosisandtoenhanceliver
regeneration [64].
MSCs have been proposed for the treatment of liver cir-
rhosis, characterized by distortion of the hepatic architecture
and formation of regenerative nodules. Liver cirrhosis is
generally considered an irreversible process and represents
a frequent cause of death worldwide [65]. The autologous
MSC injection could be a valid alternative to OLT in the
treatment of liver cirrhosis. Indeed, several animal studies
and clinical trials have demonstrated that MSCs have the
potential to reverse the ﬁbrotic process by inhibiting collagen
deposition and transforming growth factor-β1p r o d u c t i o n
[11, 66, 67]. The molecular mechanism underlying the
antiﬁbrotic properties of MSCs can mainly reside in the high
expression levels of matrix metalloproteinase (MMPs), espe-
cially MMP-9, which may directly degrade the extracellular
matrix and lead to hepatic stellate cell apoptosis [68, 69].
Recently, Pan et al. have shown that BM-MSCs were able
to attenuate liver ﬁbrosis by a direct suppression of hepatic
stellate cell activation through the inhibition of delta-like 1
(Dlk1)protein,amemberoftheEGF-likefamilyofhomeotic
proteins, in a carbon-tetrachloride- (CCl4-) induced liver
ﬁbrosis animal model [70]. In addition, Mohamadnejad
and colleagues have conducted a phase 1 clinical trial to
determine the safety and feasibility of MSC peripheral vein
infusion in patients with decompensated liver cirrhosis: liver
f u n c t i o na n dM E L Ds c o r e sw e r ei m p r o v e di nh a l fo ft h e
patients after six months [71].
Despite these encouraging results, the use of MSCs in
the hepatologic clinical practice is hampered by the inability
to monitor the transplanted cells within the patients and
by the lack of standardized clinical protocols. Moreover, theJournal of Biomedicine and Biotechnology 5
antiﬁbroticeﬀectofMSCsisstilldebated,asMSCscouldalso
potentially diﬀerentiate into ﬁbrogenic cells [13, 72].
6.MSCs inLiverTransplantation:
Risks andBeneﬁts
Transplantation tolerance is an important goal in the eﬀort
to reduce long-term morbidity and mortality in organ-
transplant recipients. MSCs can be induced toward hep-
atic diﬀerentiation ex vivo and used as a potential valid
alternative or a bridging to OLT [10–12], as they could
preventallograftrejection.SuchpotentialityisbasedonMSC
immunomodulatory properties along with their healing and
trophic functions, which could help to minimize ischemia,
I/R, and inﬂammation [15, 73]. The immunomodulatory
eﬀect exerted by MSCs on T-lymphocyte response appears
to be of primary importance in their ability to prevent
allograft rejection. As previously discussed, MSCs suppress
the proliferation and function of cytotoxic T lymphocytes
while promoting the activities of helper and regulatory T
lymphocytes. The precise mechanisms responsible for this
eﬀect and whether or not it persists long-term remain to be
determined, and further studies are needed to address this
issue.
An additional beneﬁt to the use of MSCs for the pre-
vention of solid organ allograft immunorejection is that
infusion of these cells at the time of organ transplantation
may have the potential to promote a state of immunologic
chimerism and long-term tolerance of the transplanted
organ by the host immune system [74]. This was achieved
in distinct animal models and, in a few notable cases, was
associated with long-term graft survival in the absence of
immunosuppression [74–76].
Despite the important beneﬁts arising from the use of
MSC-based therapy, there are still safety issues to debate
about, in particular regarding the long-term eﬀects on
immune function and the tumorigenic risk.
Several evidences suggest that MSCs might promote
tumor growth via transformation, suppression of the antitu-
mor immune response, and direct trophic action on tumor
cells [77–86]. The transplantation into nude mice of colon
cancer cells mixed with MSCs resulted in larger tumors than
did transplantation of cancer cells alone [85]. This eﬀect was
associatedwithahigherdegreeofneoangiogenesisandlower
apoptoticindexesinthetumormass.MSCswererecruitedby
colon cancer cells, and in turn they stimulated the migration
and invasion of tumor cells through the release of soluble
factors [85]. The proangiogenic properties of MSCs can be
due to their potential to diﬀerentiate into pericytes [86]
and, perhaps, endothelial cells, along with the secretion of
angiogenic growth factors, including vascular endothelial
growth factor, ﬁbroblast-derived growth factor, platelet-
derived growth factor, and stromal-derived factor-1 [87].
Moreover, MSCs can provide a stromal scaﬀold for growing
tumors, being a source of carcinoma-associated ﬁbroblasts
(CAFs), implicated in important aspects of epithelial solid
tumorbiologysuchasneoplasticprogression,tumorgrowth,
angiogenesis, and metastasis [88].
However, MSCs immunomodulatory properties may
play a potent antitumor eﬀect [89–98]. The exact mecha-
nisms behind the tumor suppressive eﬀects of MSCs are not
yet entirely clear, but appear to be related to the modulation
of the inﬂammatory environment that characterizes many
tumors [97]. Moreover, MSCs may exert non-immune-
related eﬀects, since they are able to interact with cancer
cells and inhibit intracellular signaling pathways associated
with cell growth and division [97, 98]. In a study by Abdel
Aziz and colleagues, the infusion of MSCs, in a rat model
of hepatocellular carcinoma, resulted in tumor suppressive
eﬀects by downregulation of Wnt signaling target genes
related to antiapoptosis, mitogenesis, cell proliferation, and
cellcycleregulation.Thisresultedintheameliorationofboth
liver histopathological features and function [99].
7. Concluding Remarks
MSCs are considered a potentially relevant therapeutic tool
for the treatment of liver diseases, given their high degree of
plasticity and immunomodulatory properties. MSCs could
represent an alternative to OLT and/or an adjuvant therapy
in the prevention of allograft liver rejection. However further
studies in vitro as well in vivo are needed to achieve a better
understanding of the potential beneﬁts and risks of MSCs
therapeutic use in clinical settings.
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